Literature DB >> 20499211

Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera.

Gholamreza Toogeh1, Shirin Ferdowsi, Fatemeh Naadali, Kamran Alimoghaddam, Ardeshir Ghavamzadeh, Reza Shirkoohi, Seyed H Ghaffari.   

Abstract

In 2007, a 27-year-old woman presented with mild splenomegaly. Blood counts showed hemoglobin (Hb): 17.8 g/dl, HCT: 56% and Red blood cells: 6.45×10(12)/L. Bone marrow examination disclosed a hypercellular marrow. Molecular analysis showed the presence of the JAK2 V617F mutation and BCR-ABL/BCR mRNA b3a2 transcript. A diagnosis of BCR-ABL-positive polycythemia vera (PV) was made. In 2009, she had nulipar pregnancy and treated with interferon-alpha. She delivered a healthy girl infant at 37 weeks. This case report suggests that in a PV pregnant woman with a concomitant presence of JAK2 V617F mutation and BCR-ABL translocation, the administration of interferon during the pregnancy could lead to a safe pregnancy and delivery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20499211     DOI: 10.1007/s12032-010-9570-8

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  50 in total

1.  Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report.

Authors:  C Baykal; N Zengin; F Coşkun; N Güler; A Ayhan
Journal:  Eur J Gynaecol Oncol       Date:  2000       Impact factor: 0.196

2.  Exposure to hydroxyurea during pregnancy: a case series.

Authors:  C Thauvin-Robinet; C Maingueneau; E Robert; E Elefant; H Guy; D Caillot; R O Casasnovas; S Douvier; A Nivelon-Chevallier
Journal:  Leukemia       Date:  2001-08       Impact factor: 11.528

3.  JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.

Authors:  N Cambier; A Renneville; T Cazaentre; V Soenen; C Cossement; S Giraudier; N Grardel; J-L Laï; C Rose; C Preudhomme
Journal:  Leukemia       Date:  2008-02-21       Impact factor: 11.528

4.  Philadelphia chromosome in essential thrombocythemia?

Authors:  R Sarode; N Marwaha; R K Gupta; G Garewal
Journal:  Am J Hematol       Date:  1989-01       Impact factor: 10.047

5.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

6.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

7.  Alpha 2b-interferon therapy and pregnancy--report of a case of essential thrombocythemia.

Authors:  S Pardini; F Dore; M Murineddu; S Bontigli; M Longinotti; B Grigliotti; B Spano
Journal:  Am J Hematol       Date:  1993-05       Impact factor: 10.047

8.  Polycythemia rubra vera in pregnancy.

Authors:  A L Centrone; R N Freda; L McGowan
Journal:  Obstet Gynecol       Date:  1967-11       Impact factor: 7.661

9.  Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.

Authors:  Marjan Yaghmaie; Seyed H Ghaffari; Ardashir Ghavamzadeh; Kamran Alimoghaddam; Mohammad Jahani; Seyed-Asadollah Mousavi; Masoud Irvani; Babak Bahar; Isa Bibordi
Journal:  Arch Iran Med       Date:  2008-05       Impact factor: 1.354

10.  Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome.

Authors:  D B Stoll; P Peterson; R Exten; J Laszlo; A V Pisciotta; J T Ellis; P White; K Vaidya; M Bozdech; S Murphy
Journal:  Am J Hematol       Date:  1988-02       Impact factor: 10.047

View more
  5 in total

1.  Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Authors:  You-Wen Qin; Yi-Ning Yang; Su Li; Chun Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-11       Impact factor: 0.900

2.  Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Authors:  Craig R Soderquist; Mark D Ewalt; David R Czuchlewski; Julia T Geyer; Heesun J Rogers; Eric D Hsi; Sa A Wang; Carlos E Bueso-Ramos; Attilio Orazi; Daniel A Arber; Elizabeth O Hexner; Daria V Babushok; Adam Bagg
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

3.  Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.

Authors:  Yoo Jin Lee; Joon Ho Moon; Ho Cheol Shin; Jong Won Seo; Seo Ae Han; Sang Kyeong Seo; Sang Kyun Sohn
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

4.  Emergence of BCR-ABL1 Chronic Myeloid Leukemia in a JAK2-V617F Polycythemia Vera.

Authors:  Mariana Lorenzo; Sofia Grille; Mariana Stevenazzi
Journal:  J Hematol       Date:  2020-04-23

5.  Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up.

Authors:  Katia Borgia Barbosa Pagnano; Márcia Torresan Delamain; Mariana Munari Magnus; José Vassallo; Carmino Antonio DE Souza; Daiane DE Almeida; Irene Lorand-Metze
Journal:  Oncol Lett       Date:  2016-05-26       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.